PL1899377T3 - Humanizowane przeciwciała specyficzne dla nogo-a i ich zastosowania farmaceutyczne - Google Patents

Humanizowane przeciwciała specyficzne dla nogo-a i ich zastosowania farmaceutyczne

Info

Publication number
PL1899377T3
PL1899377T3 PL06776123T PL06776123T PL1899377T3 PL 1899377 T3 PL1899377 T3 PL 1899377T3 PL 06776123 T PL06776123 T PL 06776123T PL 06776123 T PL06776123 T PL 06776123T PL 1899377 T3 PL1899377 T3 PL 1899377T3
Authority
PL
Poland
Prior art keywords
phrarmaceutical
nogo
antibodies specific
humanised antibodies
humanised
Prior art date
Application number
PL06776123T
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Paul Andrew Hamblin
Farhana Hussain
Alan Peter Lewis
Ruth Mcadam
Rabinder Prinjha
Paul Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0513766A external-priority patent/GB0513766D0/en
Priority claimed from GB0525448A external-priority patent/GB0525448D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL1899377T3 publication Critical patent/PL1899377T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06776123T 2005-07-05 2006-07-03 Humanizowane przeciwciała specyficzne dla nogo-a i ich zastosowania farmaceutyczne PL1899377T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0513766A GB0513766D0 (en) 2005-07-05 2005-07-05 Immunoglobulins
GB0525448A GB0525448D0 (en) 2005-12-14 2005-12-14 Immunoglobulins
EP06776123A EP1899377B1 (en) 2005-07-05 2006-07-03 Humanised antibodies specific for nogo-a and phrarmaceutical uses thereof
PCT/EP2006/006535 WO2007003421A2 (en) 2005-07-05 2006-07-03 Humanised antibodies specific for nogo-a and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
PL1899377T3 true PL1899377T3 (pl) 2013-01-31

Family

ID=37604821

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06776123T PL1899377T3 (pl) 2005-07-05 2006-07-03 Humanizowane przeciwciała specyficzne dla nogo-a i ich zastosowania farmaceutyczne

Country Status (21)

Country Link
EP (1) EP1899377B1 (pl)
JP (1) JP2009500363A (pl)
KR (1) KR20080030960A (pl)
AU (1) AU2006265276B2 (pl)
BR (1) BRPI0612734A2 (pl)
CA (1) CA2614076A1 (pl)
CR (1) CR9623A (pl)
CY (1) CY1113310T1 (pl)
DK (1) DK1899377T3 (pl)
EA (1) EA014291B1 (pl)
ES (1) ES2391902T3 (pl)
HR (1) HRP20120851T1 (pl)
IL (1) IL188282A (pl)
MA (1) MA29625B1 (pl)
NO (1) NO20076663L (pl)
NZ (1) NZ564567A (pl)
PL (1) PL1899377T3 (pl)
PT (1) PT1899377E (pl)
SG (1) SG162829A1 (pl)
SI (1) SI1899377T1 (pl)
WO (1) WO2007003421A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
CA2704357C (en) * 2007-11-02 2016-06-21 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
CA2730473A1 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
TWI772724B (zh) 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
NZ548013A (en) * 2003-12-22 2009-04-30 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
KR20080030960A (ko) 2008-04-07
AU2006265276B2 (en) 2011-10-13
EA014291B1 (ru) 2010-10-29
SI1899377T1 (sl) 2012-12-31
EP1899377B1 (en) 2012-08-22
CA2614076A1 (en) 2007-01-11
EP1899377A2 (en) 2008-03-19
ES2391902T3 (es) 2012-11-30
WO2007003421A2 (en) 2007-01-11
SG162829A1 (en) 2010-07-29
CY1113310T1 (el) 2016-04-13
JP2009500363A (ja) 2009-01-08
NZ564567A (en) 2010-09-30
IL188282A (en) 2011-04-28
PT1899377E (pt) 2012-11-20
MA29625B1 (fr) 2008-07-01
HRP20120851T1 (hr) 2012-11-30
NO20076663L (no) 2008-02-27
WO2007003421A3 (en) 2007-04-12
IL188282A0 (en) 2008-04-13
CR9623A (es) 2008-04-10
DK1899377T3 (da) 2012-11-12
HK1115598A1 (en) 2008-12-05
EA200702634A1 (ru) 2008-06-30
AU2006265276A1 (en) 2007-01-11
BRPI0612734A2 (pt) 2010-11-30

Similar Documents

Publication Publication Date Title
IL272883A (en) Monoclonal antibodies and their uses
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
ZA200809662B (en) Modified humanised anti-interleukin-18 antibodies
SG10201404801YA (en) Monoclonal antibody
IL240245A (en) 5t4 antibodies and their uses
IL222922A (en) Antibodies against neurophilin-1 and their use
IL206710A0 (en) Il-31 monoclonal antibodies
IL184024A0 (en) Irta-5 antibodies and their uses
ZA200900514B (en) Anti-iL-6 monoclonal antibodies and uses thereof
IL179672A0 (en) Anti-cd3 antibodies
IL234657A0 (en) Antibodies to p-cadherin
IL197928A0 (en) Antibodies and immunoconjugates and uses therefor
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
GB0517487D0 (en) Antibodies
EP2077325A4 (en) MONOCLONAL ANTIBODY AND ITS USE
SI2094728T1 (sl) Postopki za uporabo za humano-adaptivnost monoklonskih protiteles
ZA201103941B (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
ZA200800047B (en) Humanised antibodies specific for NOGO-A and pharmaceutical uses thereof
SI1899377T1 (sl) Humanizirana protitelesa, specifična za NOGO-A, in njihove farmacevtske uporabe
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en) Antibodies
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
HK1113802A (en) Anti-trkb monoclonal antibodies and uses thereof
HK1145505A (en) Anti-chikungunya monoclonal antibodies and uses thereof